Selen Soylu

Selen Soylu

Auto-generated profile, based on publicly available information

Selen Soylu

Department of Neuroscience, Aziz Sancar Institute for Experimental Medical Research, Istanbul University, Istanbul, Türkiye

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2023 in Immunology Letters
Verified
Journal Article
Closed access
SSSelen Soylu
Selen Soylu
MCMinara Cherkezzade
Minara Cherkezzade
EAEce Akbayır
Ece Akbayır
HKHande Yüceer Korkmaz
Hande Yüceer Korkmaz
GKGizem Koral
Gizem Koral
CKCem İsmail Küçükali
Cem İsmail Küçükali

1 January 2026 in Ideggyogyaszati Szemle
Verified
Journal Article
Closed access
ZMZülfikar Memis
Zülfikar Memis
SSSelen Soylu
Selen Soylu
MBMuhammet Duran Bayar
Muhammet Duran Bayar
AŞAysel Büşra Şişman
Aysel Büşra Şişman
NSNuray Sancar
Nuray Sancar
BBBirgül Baştan
Birgül Baştan
Background and purpose – Acute ischemic stroke (AIS) is often encountered during the clinical course of coronavirus disease 2019 (COVID-19) infection. Accumulated evidence has indicated involvement of ferroptosis in AIS. Our aim was to investigate the association between serum levels of ferroptosis markers and severity of AIS in COVID-19 patients. Methods – Twenty-nine consecutively enrolled COVID-19+ pneumonia patients with AIS due to middle cerebral artery (MCA) occlusion, 25 COVID-19+ pneumonia patients without AIS and 26 AIS patients without COVID-19 infection were included. Serum levels of ferroptosis markers glutathione peroxidase 4 (GPX4), dipeptidylpeptidase-4 (DPP4) and soluble transferrin receptor 1 (sTFR1) were measured by ELISA. Results – While serum GPX4 levels were comparable among groups, COVID-19 patients with and without AIS showed significantly increased serum sTFR1 levels and COVID-19 patients with AIS showed significantly decreased serum DPP4 levels. In patients with COVID-19 and AIS, serum levels of DPP4 and sTFR1 respectively showed negative and positive correlation with levels of D-dimer and/or C-reactive protein (CRP). Levels of ferroptosis markers did not correlate with clinical/prognostic features of pneumonia or AIS. Nevertheless, COVID-19 patients with higher (≥ 131 pg/ ml) sTFR1 levels were more likely to exhibit severe pneumonia, increased clinical severity of AIS (assessed by the national institutes of health stroke and modified Rankin scales) and elevated D-dimer/CRP levels. Our results indicate TFR1 as a potential role player in both COVID-19 pneumonia and arterial thrombosis associated with COVID-19 infection. The biomarker utility of sTFR1 in these disorders should further be evaluated. Conclusion – Our results suggest that AIS associated with COVID-19 have a different pathogenesis.